Lung Cancer Diagnosis and Therapeutics Market 2018-2023
ORION MARKET RESEARCH
https://www.omrglobal.com/industry-reports/lung-cancer-diagnosis-market/
LUNG CANCER DIAGNOSIS MARKET INSIGHTS The global lung cancer diagnosis market is anticipated to grow at a CAGR of 7.4% by 2023. Lung cancer occurs when cells of the lung become abnormal and begin to grow out of control. As more cancer cells develop, they form into a tumor and spread to other areas of the body. There are two types of lung cancer; Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Several factors such as pollution, smoking, passive smoking and other factors cause lunch cancer. There are several factors that are being considered for the cause of the lung cancer such as rising pollution due to the amount of carbon particles inhaled by humans. Robust healthcare expenditure within the developed countries, increasing pollution, Government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market. Several signs and symptoms of lung cancer include coughing up blood, weight loss, chest pain, shortness of breath and others.
The lung cancer diagnosis and therapeutics market has been segmented into by type, by treatment, by diagnosis, by stages, and by end user. On the basis type, the market has been bifurcated into non-small cell lung cancer and small cell lung cancer. According to therapy, the market has been bifurcated into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. Based on diagnosis, the market has been bifurcated into CT-scan, X-rays, lung cancer screening, needle biopsy, bronchoscopy, sputum cytology and others On the basis of end user, the market has been bifurcated into multispecialty hospitals and cancer research centers. Geographically, the worldwide lung cancer diagnosis and therapeutics showcase is divided into North America, Europe, Asia-Pacific, and Rest of the World. Asia Pacific market is considered to be the fastest growing market globally. The rise in the number of cancer patients in the APAC region is considered to rise eventually enabling the lung cancer diagnosis and therapeutics market to grow. The North America and Europe are considered to be the dominating markets due to various factors such as high healthcare expenditure, development in technology, support from government, rising key players and other factors.
MARKET SEGMENTATION
Global lung cancer diagnosis and therapeutics market is segmented on the basis of, type, by therapies, by diagnosis, by end user and regional outlook. Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Type Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Therapies Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Diagnosis Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by End User Global Lung Cancer Diagnosis and Therapeutics Market Research and Analysis, by Region
THE REPORTS COVERS • Comprehensive research methodology of global lung cancer diagnosis and therapeutics • This report also includes detailed and extensive market overview with key analyst insights. • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations. • Analysis of regional regulations and other government policies impacting the global lung cancer diagnosis and therapeutics • Insights about market determinants which are stimulating the global lung cancer diagnosis and therapeutics • Detailed and extensive market segments with regional distribution of forecasted revenues. • Extensive profiles and recent developments of market players.
TABLE OF CONTENT
1.REPORT SUMMARY 1.1. RESEARCH METHODS AND TOOLS 1.2. MARKET BREAKDOWN 1.2.1. BY SEGMENTS 1.2.2. BY GEOGRAPHY 1.2.3. BY STAKEHOLDERS
TABLE OF CONTENT 2. MARKET OVERVIEW AND INSIGHTS 2.1. DEFINITION 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS 2.2.1. KEY FINDINGS 2.2.2. RECOMMENDATION 2.2.3. CONCLUSION 2.3. REGULATIONS 2.3.1. UNITED STATES 2.3.2. EUROPEAN UNION 2.3.3. CHINA 2.3.4. INDIA 2.3.5. REST OF THE WORLD 2.4. PATENT ANALYSIS
TABLE OF CONTENT 3. MARKET DETERMINANT 3.1. MOTIVATORS 3.1.1. RISING INCIDENCE OF LUNG CANCER 3.1.2. RISING UTILIZATION OF COMBINE THERAPIES FOR TREATMENT OF LUNG CANCER 3.1.3. GOVERNMENT INITIATIVES TO INCREASE AWARENESS FOR LUNG CANCER 3.1.4. RISING POLLUTION DUE TO URBANIZATION INCREASES SYMPTONS OF LUNG CANCER 3.2. RESTRAINTS 3.2.1. HIGH COST ASSOCIATED WITH THERAPIES 3.2.2. ADVERSE EFFECTS OF DRUGS DURING TREATMENT 3.3. OPPORTUNITIES 3.3.1. R&D IN MIXED THERAPIES 3.3.2. STRATEGIC ALLIANCE FOR LATE-STAGE PIPELINE
TABLE OF CONTENT 4. MARKET SEGMENTATION 4.1. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY TYPE 4.1.1. NON-SMALL CELL LUNG CANCER 4.1.1.1. ADENOCARCINOMAS 4.1.1.2. BRONCHIOLOALVEOLAR CARCINOMA 4.1.1.3. SQUAMPOUS CELL CARCINOMA 4.1.1.4. LARGE CELL CARCINOMAS 4.1.2. SMALL CELL LUNG CANCER 4.2. GLOBAL LUNG CANCER DIAGNOSIS AND THERAPEUTICS MARKET, BY THERAPY 4.2.1. CHEMOTHERAPY 4.2.2. TARGETED THERAPY 4.2.3. IMMUNOTHERAPY
TABLE OF CONTENT 5. COMPETITIVE LANDSCAPE 5.1. STRATEGY ANALYSIS 5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS 6.1. NORTH AMERICA 6.1.1. UNITED STATES 6.1.2. CANADA 6.2. EUROPE 6.2.1. UNITED KINGDOM 6.2.2. FRANCE
6.2.3. GERMANY 6.2.4. ITALY 6.2.5. SPAIN 6.2.6. REST OF EUROPE 6.3. ASIA PACIFIC 6.3.1. INDIA 6.3.2. CHINA 6.3.3. JAPAN 6.4. REST OF THE WORLD
TABLE OF CONTENT 7. COMPANY PROFILES 7.1. ABBVIE 7.2. ARQULE INC. 7.3. ASTRAZENECA PLC 7.4. BAYER 7.5. BOEHRINGER . 7.6. BRISTOL-MYERS SQUIBB 7.7. CELGENE 7.8. DAIICHI SANKYO CO. LTD. 7.9. EISAI 7.10. ELI LILLY AND COMPANY
7.11. GENENTECH 7.12. GLAXOSMITH 7.13. MERCK & CO. INC. 7.14. NOV 7.15. PFIZER 7.16. QIAGEN N.V. COMPANY 7.17. PHARMACYCLICS 7.18. ROCHE 7.19. SANOFI 7.20. TEVA PHARMACEUTICALS 7.21. VENTANA 7.22. VALEANT PHARMACEUTICALS INC. 7.23. VARIAN MEDICAL SYSTEMS INC.
CONTACT US CORPORATE OFFICE Orion Market Research Pvt. Ltd. (OMR Global) 116, Shagun Arcade, Vijay Nagar Square, Indore, Madhya Pradesh India- 452010
+1-646-755-7667 +91-780-304-0404 info@omrglobal.com www.omrglobal.com/
https://www.omrglobal.com/industry-reports/lung-cancer-diagnosis-market/